 |
|
A case of false positive octreoscan in Crohn's disease
September 22, 2008Neuroendocrine tumors, such as carcinoid tumors, overexpress somatostatin receptors in their membranes. Octreotide is an analogue whose molecule is a shortened version of somatostatin's with a high affinity for these receptors. The labelled form of octreotide is able to be imaged in scans (Octreoscan) and, therefore, pathological conditions overexpressing somatostatin receptors are easily recognized in this technique. Specifically, in the case of the detection of carcinoid tumors, the Octreoscan has sensitivity nearly to 90%.
A research article to be published on September 14, 2008 in the World Journal of Gastroenterology addresses this question. The research team led by Alberto Fernandez from POVISA Hospital in Spain presents a case of a patient with a high suspicious of ileal carcinoid tumor (according to CT-scan and colonoscopy results) with a positive Octreoscan, showing uptake in the same bowel reported as pathological in CT. The patient underwent surgery and histological analysis reported Crohn's disease.
This article is the second report of CD a cause of false positive in octeotride scan. In order to explain this abnormal uptake, immunohistochemical studies were performed but the authors did not find somatostatine receptors in the sample. In the previous report published of CD mimicking an ileal carcinoid there is no evidence that somatostatin receptors were determined.
The authors did not find any explanation, and concluded encouraging physicians to be aware of CD as a cause of false positive results of Octreoscan and that further studies should be made in order to assess the possible causes of this abnormal uptake.
World Journal of Gastroenterology
The authors did not find any explanation, and concluded encouraging physicians to be aware of CD as a cause of false positive results of Octreoscan and that further studies should be made in order to assess the possible causes of this abnormal uptake.
World Journal of Gastroenterology
Targeted tumor therapy: When antagonists do the better job
Targeted tumor therapy lobs toxic payloads directly into tumors to destroy cancer cells while leaving normal cells unharmed.
Nuclear Medicine Imaging Allows Immediate Prediction of Advanced Breast Cancer Patients' Response to Hormonal Treatment
Innovative use of somatostatin receptor scintigraphy (SRS), a nuclear medicine imaging technique looking at how the body functions at the molecular level, may provide near immediate selection of breast cancer patients for endocrine therapy and offers a new tool in fighting the disease.
Suppressing growth hormone in early adulthood may prevent cancer
A modest suppression of growth hormone and related compounds beginning in early adulthood may delay the onset or progression of several types of cancer, researchers from Wake Forest University School of Medicine and other centers reported today at ENDO 2005, the annual meeting of the Endocrine Society, in San Diego.
Nature and the Nature research journals press release
[1] Predicting stroke risk in sickle cell anemia
More Somatostatin Current Events and Somatostatin News Articles
| Role of Somatostatin-Analogues in Gastrointestinal Diseases (Digestion, 60/2) | |
| Somatostatin:Basic and Clinical Status (Serono Symposia USA) | |
 | Somatostatin Analogues: Basic and Clinical Perspectives Meeting, Sorrento, November, 1995 (Digestion) |
 | Peptides in Oncology III: Somatostatin and LH-RH Analogues This volume presents the state of the art in the use of somatostatin and LH-RH analogues in neoplastic diseases. It describes their mechanisms of action and the present clinical relevance of these approaches in cancer treatment, including structural and functional aspects. Each chapter is prepared by an expert active in the experimental and/or clinical field, so that the book comprises the most... |
| Somatostatin in Digestive Diseases: Improving the Treatment Options (Digestion) by C. Scarpignato | |
 | Somatostatin and Its Receptors -No. 190 (CIBA Foundation Symposia Series) by CIBA Foundation Symposium Somatostatin and its Receptors Chairman: S. Reichlin 1995 The cyclic tetradecapeptide hormone, somatostatin, was first characterized as the major physiological inhibitor of growth hormone release from the pituitary, but has subsequently been shown to inhibit the release of many other physiologically important compounds, including insulin, glucagon, gastrin and secretin. It is therefore a major... |
| The Role of Somatostatin and Octreotide in Pancreatic Disease: Proceedings of a Symposium During the Epc Meeting October 12, 1992 Ulm, Germany (Dige) by M. W. Buchler, Kp Malfertheiner | |
 | Somatostatin Analogs in Cancer Management (Chemotherapy Supplement) Although cytotoxic chemotherapy is very effective in the management of certain neoplasms such as testicular cancer, the efficacy of this therapeutic modality in the treatment of many common neoplasms is limited. Cure of macroscopic metastatic disease is extremely rare, and palliation of symptoms by chemotherapy can be problematic since the toxicity of the treatment often mitigates any improvement... |
| Zur Spinalen Infusion Von Opiaten Und Somatostatin -- Spinal Infusion of Opiates and Somatostatin | |
| Somatostatin (DISCONTINUED (Basic and Clinical Aspects of Neuroscience)) by CLAUDE WEIL |
| © 2009 BrightSurf.com |